Related Experiment Video
Updated: Mar 14, 2026
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Prevalence of the metabolic syndrome in rheumatoid arthritis
Mustafa Özmen1, Özlem Yersal2, Serpil Öztürk2
1Department of Rheumatology, İzmir Atatürk Training and Research Hospital, İzmir, Turkey.
Insights
Metabolic syndrome (MetS) is more prevalent in rheumatoid arthritis (RA) patients, increasing cardiovascular disease (CVD) risk. Early MetS screening in RA patients is recommended for better CVD risk management.
Area of Science:
- Rheumatology
- Cardiology
- Metabolic Diseases
Background:
- Rheumatoid arthritis (RA) patients have a higher prevalence of cardiovascular disease (CVD).
- Metabolic syndrome (MetS) is a cluster of CVD risk factors.
- Causal factors for increased CVD risk in RA are not fully understood.
Purpose of the Study:
- To investigate the prevalence of MetS in RA patients.
- To explore the relationship between MetS and disease-related factors in RA.
Main Methods:
- 52 RA patients and 30 healthy controls were studied.
- MetS was defined using National Cholesterol Education Program (NCEP-ATP III) and modified World Health Organization (WHO) criteria.
- RA disease activity was assessed using DAS28 and functional status by HAQ.
Main Results:
- Modified WHO criteria showed a significantly higher MetS prevalence in RA patients (28.8%) versus controls (9.7%).
- Central obesity and hypertension were more frequent in RA patients by both criteria.
- RA patients with MetS had higher blood pressure, BMI, and smoking frequency.
Conclusions:
- MetS is more prevalent in RA patients, particularly when using modified WHO criteria.
- Screening RA patients for MetS may help manage their elevated CVD risk.
Objective:
Patients with rheumatoid arthritis (RA) experience a markedly increased prevalence of cardiovascular disease (CVD), but the causal factors have yet to be completely elucidated. Metabolic syndrome (MetS) is a cluster of risk factors of CVD and identifies additional cardiovascular risk beyond the sum of its individual components. In this study, we investigated the prevalence of MetS and its possible relationship with disease-related factors in patients with RA.
Material And Methods:
Fifty-two patients with RA and 30 age- and sex-matched healthy controls were studied. Adult Treatment Panel III of the National Cholesterol Education Program (NCEP-ATP III) and modified World Health Organization (WHO) criteria were used to define MetS. RA disease activity is assessed by the disease activity score of 28 joints (DAS28), and the functional status of patients was evaluated by Health Assessment Questionnaire (HAQ).
Results:
Although there was no difference between groups regarding the frequency of MetS according to NCEP-ATP III criteria (17.3% and 6.5% in RA and control groups, respectively (p=0.158)) if modified WHO criteria were used, the prevalence of MetS was significantly higher in patients with RA (28.8%) than in controls (9.7%) (p=0.04). Central obesity and hypertension were found to be more frequent in patients with RA by both NCEP-ATP III and WHO criteria. RA patients with MetS had higher systolic and diastolic blood pressure, BMI and frequency of smoking than patients without MetS. Disease-related factors were similar in RA patients with or without MetS.
Conclusion:
The evaluation of patients with RA for MetS, which is a multidimensional risk factor of CVD, may be beneficial.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:23Rheumatic Heart Disease I: Introduction
01:20The JAK-STAT Signaling Pathway
01:30Coronary Artery Disease I: Introduction
01:21Rheumatic Heart Disease III: Medical Management